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Several steps of HIV-1 replication critically depend on cholesterol. HIV infection is associated with profound changes in
lipid and lipoprotein metabolism and an increased risk of coronary artery disease. Whereas numerous studies have
investigated the role of anti-HIV drugs in lipodystrophy and dyslipidemia, the effects of HIV infection on cellular
cholesterol metabolism remain uncharacterized. Here, we demonstrate that HIV-1 impairs ATP-binding cassette
transporter A1 (ABCA1)-dependent cholesterol efflux from human macrophages, a condition previously shown to be
highly atherogenic. In HIV-1–infected cells, this effect was mediated by Nef. Transfection of murine macrophages with
Nef impaired cholesterol efflux from these cells. At least two mechanisms were found to be responsible for this
phenomenon: first, HIV infection and transfection with Nef induced post-transcriptional down-regulation of ABCA1;
and second, Nef caused redistribution of ABCA1 to the plasma membrane and inhibited internalization of
apolipoprotein A-I. Binding of Nef to ABCA1 was required for down-regulation and redistribution of ABCA1. HIV-
infected and Nef-transfected macrophages accumulated substantial amounts of lipids, thus resembling foam cells. The
contribution of HIV-infected macrophages to the pathogenesis of atherosclerosis was supported by the presence of
HIV-positive foam cells in atherosclerotic plaques of HIV-infected patients. Stimulation of cholesterol efflux from
macrophages significantly reduced infectivity of the virions produced by these cells, and this effect correlated with a
decreased amount of virion-associated cholesterol, suggesting that impairment of cholesterol efflux is essential to
ensure proper cholesterol content in nascent HIV particles. These results reveal a previously unrecognized
dysregulation of intracellular lipid metabolism in HIV-infected macrophages and identify Nef and ABCA1 as the key
players responsible for this effect. Our findings have implications for pathogenesis of both HIV disease and
atherosclerosis, because they reveal the role of cholesterol efflux impairment in HIV infectivity and suggest a possible
mechanism by which HIV infection of macrophages may contribute to increased risk of atherosclerosis in HIV-infected
patients.
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Introduction
Macrophage cells and cholesterol play a central role in the
pathogenesis of two diseases, AIDS and atherosclerosis.
Macrophages are among the main targets of HIV in the
body, and HIV assembly and budding, as well as infection of
new target cells, all depend on plasma membrane cholesterol.
Depletion of cellular cholesterol markedly and speciﬁcally
reduces HIV-1 particle production [1,2], and cholesterol-
sequestering drugs, such as b-cyclodextrin, render the virus
incompetent for cell entry [3,4]. Therefore, regulating
cholesterol delivery to nascent virions would be highly
beneﬁcial for the virus. Some clues to potential mechanisms
that may be employed by HIV to achieve this goal have been
provided recently when it was demonstrated that HIV-1
accessory protein Nef binds cholesterol and may deliver it to
the site of virion assembly at the plasma membrane [5].
However, little is known about the relation of this mechanism
to major cellular cholesterol trafﬁcking pathways and about
the effect of HIV infection on lipid metabolism in the host
cells.
Increased risk of atherosclerosis and coronary artery
disease (CAD) is a recognized clinical problem in HIV-
infected patients [6–10]. A key element of atherosclerotic
plaque is formation of foam cells [11], the majority of which
are macrophages overloaded with cholesterol. Foam cells
undergo apoptosis, necrosis, and calciﬁcation, and cholester-
ol released from foam cells forms the lipid-rich core of the
plaque. Interestingly, foam cells are less conducive than
macrophages to growth of certain pathogens, such as
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PLoS BIOLOGYChlamydia pneumoniae [12], suggesting that they may contribute
to antibacterial response of the organism. One of the main
causes of foam cell formation and accumulation of choles-
terol in the vessel wall may be dyslipidemia, especially high
levels of very low-density lipoprotein (VLDL) and low-density
lipoprotein (LDL), as well as low levels of high-density
lipoprotein (HDL) [13], and/or impairment of intracellular
cholesterol metabolism. Dyslipidemia caused by antiretrovi-
ral drugs, in particular protease inhibitors (PIs) [14], is a
known risk factor in pathogenesis of CAD in HIV-infected
patients. One mechanism of PI treatment–dependent dysli-
pidemia is inhibition of degradation of proteins involved in
metabolism of cholesterol and triglycerides, such as apolipo-
protein B [15] or the adipocyte determination- and differ-
entiation-dependent factor 1/sterol regulatory element
binding protein 1 [16]. In addition to causing dyslipidemia,
PIs may contribute to initiation of atherosclerosis by
affecting intracellular metabolism of cholesterol via up-
regulation of the scavenger receptor CD36 and the subse-
quent accumulation of sterol in macrophages [17]. Therefore,
PIs affect both extra- and intracellular pathways of choles-
terol metabolism and are likely an important factor in
pathogenesis of atherosclerosis in HIV-infected patients.
However, a number of clinical reports found a correlation
between heart disease and HIV viral load, and detected an
increased risk of CAD in patients not treated with PIs or even
in drug-naive HIV-infected individuals [18,19]. Recent results
support the role of HIV infection as an independent risk
factor of CAD [7,9,10,20–22], but the mechanisms of this
atherogenic effect of HIV remain unknown.
In this report, we identify one such mechanism. We show
that HIV, via its accessory protein Nef, affects normal
function of ATP-binding cassette transporter A1 (ABCA1)
and consequently impairs cholesterol efﬂux from infected
macrophages. Previous studies demonstrated the key role of
ABCA1 in reverse cholesterol transport and found that
functional mutations in ABCA1 cause Tangier disease, which
is characterized by severe HDL deﬁciency, accumulation of
sterols in tissue macrophages, and accelerated atherosclerosis
[23]. The effect of HIV-1 on ABCA1 is consistent with ABCA1
inhibition described for viral [24] and bacterial [25] in-
fections; however, the mechanism of impairment is unique
for HIV. As a result of ABCA1 inhibition, HIV-infected
macrophages accumulate lipids and transform into foam
cells, a step that may contribute to the increased risk of
atherosclerotic plaque formation. Our results also suggest
that cholesterol efﬂux impairment may be a mechanism that
ensures access of nascent virions to intracellular cholesterol,
which is critical for HIV infectivity. Therefore, pharmaco-
logical stimulation of cholesterol efﬂux may be considered as
a novel anti-HIV therapeutic strategy.
Results
Impairment of Cholesterol Efflux in HIV-Infected
Macrophages
Cholesterol efﬂux is a pathway for removing excessive
cholesterol from cells to extracellular acceptors. It is the ﬁrst
step of reverse cholesterol transport, and it plays a key role in
maintaining cell cholesterol homeostasis. Impairment of
cholesterol efﬂux leads to accumulation of intracellular
cholesterol [26] and development of atherosclerosis in animal
models [27] and in humans [28,29]. Analysis of cholesterol
efﬂux from monocyte-derived macrophages infected in vitro
with HIV-1 ADA [30] demonstrated a substantial inhibition of
apolipoprotein A-I (apoA-I)-speciﬁc efﬂux (Figure 1A). A
similar effect was observed in macrophages infected with two
primary macrophage-tropic HIV-1 strains, Yu-2 and
92US660, indicating that impairment of cholesterol efﬂux is
a general feature of HIV-1 replication in macrophages
(Figure 1A). The level of cholesterol efﬂux inhibition
correlated with the level of virus replication (Figure 1A).
Importantly, at the time of analysis (21 d after infection),
80%–90% of the cells infected with ADA and Yu-2 viruses
were p24
þ(only 20% of the cells infected with 92US660 strain
were p24
þ at that time), indicating that reverse transcription
(RT) values in these infections reﬂected the amount of virus
Figure 1. HIV-1 Nef Impairs Cholesterol Efflux from Macrophages
(A) Monocyte-derived macrophages were inoculated with indicated HIV-
1 strains equalized according to RT activity and cultivated for 21 d (RT
activity in the culture supernatants on day 21 is shown beneath the bars).
Mock-infected cells were incubated with virus-free medium. Specific
cholesterol efflux to apoA-I (30 lg/ml) was performed for 12 h and
analyzed as described in Materials and Methods. Results are presented as
percentage of efflux from mock-infected cells (taken as 100%) and are
mean 6 standard deviation (SD) of triplicate determinations. An asterisk
(*) indicates p , 0.001
(B) Monocyte-derived macrophages were inoculated with VSV-G-
pseudotyped HIV-1 SF2 either deficient in Nef (SF2.DNef) or carrying
WT Nef (SF2.wt). Specific cholesterol efflux to apoA-I (30 lg/ml) was
analyzed on day 6 after inoculation using the same procedure as
described in (A). p24 concentration in the culture medium is shown
beneath the bars. Results are presented as percentage of efflux from
mock-infected cells (taken as 100%) and are mean 6 SD of triplicate
determinations. An asterisk (*) indicates p , 0.001.
(C) RAW 264.7 cells were transfected with plasmids expressing indicated
Nef variants or an empty vector (mock-transfection). Twenty-four hours
after transfection, LXR agonist, TO-901317 (1 lmol/L), was added.
Cholesterol efflux to apoA-I (30 lg/ml) was performed for 3 h with cells
48 h after transfection as described in Materials and Methods. Means 6
SD of quadruplicate determinations are shown. An asterisk (*) indicates p
, 0.001.
(D) Immunoblotting of RAW 264.7 cells transfected with empty vector
(mock), WT Nef derived from HIV-1 strain SF2 (Nef.wt), or Nef.G2A
mutant, and stained with anti-Nef antibodies.
DOI: 10.1371/journal.pbio.0040365.g001
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depended on the level of virus protein expression.
Nef Is Critical for Cholesterol Efflux Impairment
Previous studies demonstrated that the HIV-1 protein Nef
can directly bind cholesterol and suggested that in CD4
þ T
cells, Nef may be involved in transporting cholesterol to the
sites of HIV assembly at the plasma membrane [5]. To test the
role of Nef in the observed impairment of cholesterol efﬂux
from macrophages, we infected macrophages with HIV-1 SF2
constructs carrying a mutated or a functional Nef gene. To
ensure similar levels of infection, the constructs were
pseudotyped by the glycoprotein of vesicular stomatitis virus
(VSV-G), which targets HIV-1 entry to an endocytic pathway,
thus eliminating the requirement for Nef in the early steps of
infection [31]. Under these one-cycle replication conditions,
both viruses infected about 40% of cells and produced similar
levels of p24 (Figure 1B). Cholesterol efﬂux to apoA-I was
substantially reduced in the culture infected with the Nef-
positive virus (wild type [WT]), whereas in the culture
infected with Nef-deﬁcient virus (DNef), it was similar to
the level observed in uninfected cells (Figure 1B). This result
indicates that Nef is necessary for HIV-mediated impairment
of cholesterol efﬂux.
To determine whether Nef is sufﬁcient for the observed
effect, we transiently transfected murine macrophages RAW
264.7 with constructs expressing SF2-derived Nef and
stimulated ABCA1 expression in these cells by liver X
receptor (LXR) agonist TO-901317. Cholesterol efﬂux to
apoA-I from Nef-transfected RAW 264.7 macrophages was
signiﬁcantly reduced (by more than 50%) compared to cells
transfected with an empty vector (mock transfection) (Figure
1C). This result indicates that expression of Nef is sufﬁcient
to impair cholesterol efﬂux from macrophages. Interestingly,
Nef mutant Nef.G2A, defective in myristoylation and mem-
brane localization [5], was not effective in impairing
cholesterol efﬂux (Figure 1C) despite levels of expression
being similar to that of WT Nef (Figure 1D). Cholesterol
efﬂux impairment in Nef-transfected RAW cells was less than
in HIV-infected macrophages, likely due to differences
between these cell types.
Nef Specifically Targets ABCA1-Dependent Cholesterol
Efflux
Speciﬁc efﬂux of cholesterol from cells is mediated by the
members of the family of ATP-binding cassette (ABC)
transporters. The ABCA1 transporter is responsible for
lipidation of lipid-poor apoA-I with cellular lipids [32],
whereas ABCG1 controls efﬂux to mature HDL [33]. Our
ﬁnding that Nef inhibits cholesterol efﬂux to apoA-I (Figure
1) suggests that ABCA1 may be the speciﬁc target of Nef.
Consistent with this notion, cholesterol efﬂux to HDL
(controlled by ABCG1) from HIV-infected macrophages was
not signiﬁcantly impaired (Figure 2A). Furthermore, phos-
pholipid efﬂux, which is dependent on ABCA1 [34], from Nef-
transfected RAW 264.7 macrophages was reduced (Figure 2B),
similar to the effect of Nef on cholesterol efﬂux (Figure 1C).
In addition, Nef did not affect cholesterol efﬂux from RAW
264.7 cells in which ABCA1 expression was not stimulated
(Figure 2C) and consequently was very low.
The notion that ABCA1-mediated efﬂux is the target of Nef
was further supported by experiments in HeLa cells, which do
not express ABC transporters and have very low background
cholesterol efﬂux to apoA-I [35]. Consistent with a previous
report [36], transfection of HeLa cells with ABCA1 signiﬁ-
cantly enhanced cholesterol efﬂux to apoA-I, whereas co-
transfection with Nef derived from SF2 or LAI strains of HIV-
1 brought the efﬂux back to the level observed in mock-
transfected cells (Figure 2D). Importantly, NefLAI, which was
expressed to higher levels than NefSF2 (Figure 2D), was more
Figure 2. Nef Targets ABCA1-Dependent Cholesterol Efflux
(A) Cholesterol efflux to HDL (30 lg/ml) was measured from HIV-1 ADA-
infected and mock-infected macrophages used also to measure efflux to
apoA-I in Figure 1A.
(B) Impairment of phospholipid efflux in Nef-transfected RAW 264.7 cells.
RAW 264.7 cells were transfected with plasmid expressing HIV-1 SF2-
derived Nef or empty vector (mock-transfection). Phospholipid efflux to
apoA-I (30 lg/ml) was measured as described in Methods. Means 6 SD
of quadruplicate determinations are shown. An asterisk (*) indicates p ,
0.001.
(C) Nef does not decrease cholesterol efflux in RAW 264.7 cells not
treated with LXR agonist. Experiment was performed using HIV-1 SF2-
derived Nef as described in Figure 1C, except that LXR agonist was not
added.
(D) Cholesterol efflux to apoA-I from HeLa cells. HeLa cells were either
mock-transfected (mock) or co-transfected with ABCA1 and empty
vector (ABCA1), or vector expressing Nef derived from HIV-1 SF2 (ABCA1
þ NefSF2) or LAI strains (ABCA1 þ NefLAI); cholesterol efflux to apoA-I
was analyzed. An asterisk (*) indicates p , 0.001 (versus cells without
ABCA1); a number sign (#) indicates p , 0.001 (versus cells without Nef).
Expression of Nef determined by Western blot is shown beneath the
bars.
(E) Cholesterol efflux to HDL from HeLa cells. Experiment was performed
as in (D), except that ABCG1 was used instead of ABCA1, and HDL (30 lg/
ml) instead of apoA-I was used as cholesterol acceptor. An asterisk (*)
indicates p , 0.01 (versus cells without ABCG1).
DOI: 10.1371/journal.pbio.0040365.g002
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experiment testing the effect of Nef on ABCG1-directed
cholesterol efﬂux showed stimulation of cholesterol efﬂux to
HDL after transfection of HeLa cells with ABCG1, but did not
reveal signiﬁcant inhibition by Nef (Figure 2E). Therefore, we
conclude that Nef speciﬁcally targets ABCA1-dependent
cholesterol efﬂux.
Nef Down-Regulates ABCA1
Since ABCA1 appears to be the target of Nef, we tested
ABCA1 abundance (by Western blotting) and transcription
(by real-time RT-PCR) in HIV-infected human macrophages
and Nef-transfected RAW 264.7 cells. Analysis of ABCA1 in
macrophages at the peak of HIV-1 ADA replication showed a
substantial decrease of ABCA1 abundance (Figure 3A).
Importantly, abundance of two other proteins involved in
cholesterol efﬂux to HDL, ABCG1 and scavenger receptor B1
(SR-B1), was not affected by HIV infection (Figure 3A),
consistent with speciﬁc targeting of the ABCA1-dependent
pathway by the virus. A similar phenomenon was observed in
Nef-transfected RAW 264.7 macrophages, although the effect
was less pronounced (approximately 50% reduction in
ABCA1 abundance when assessed by densitometry of the
Western blot) (Figure 3B). The Nef.G2A mutant, which was
inactive in cholesterol efﬂux impairment (Figure 1C), was also
inactive in depleting ABCA1. RT-PCR analysis revealed a
signiﬁcant increase of ABCA1 mRNA in HIV-infected (Figure
3C) or Nef-transfected (Figure 3D) cells, which likely reﬂects a
compensatory response for the loss of ABCA1 [37]. This
observation rules out a suppressive effect of Nef on ABCA1
transcription and suggests a post-transcriptional down-
regulation of ABCA1 by Nef. Therefore, down-regulation of
ABCA1 is one of the mechanisms responsible for impairment
of cholesterol efﬂux by HIV-1.
Nef Alters Intracellular Distribution of ABCA1
Although down-regulation of ABCA1 alone would account
for a substantial part of the inhibition of cholesterol efﬂux,
we further found that intracellular distribution of ABCA1
was also affected by HIV infection. Recent reports established
Figure 3. Nef Induces Down-Modulation of ABCA1
(A) Human monocyte-derived macrophages were infected with HIV-1 ADA or mock-infected and cultured for 14 d (RT in culture supernatant was 4,000
cpm/ll). ABCA1, ABCG1, SR-B1, and b-actin (loading control) were analyzed by Western blotting.
(B) RAW 264.7 cells were transfected with vector expressing HIV-1 SF2-derived Nef (either WT or carrying a G2A mutation) or empty vector (mock).
Twenty-four hours after transfection, cells were stimulated with TO-901317 (1 lM) and 24 h later, were analyzed by Western blotting for ABCA1 and b-
actin (loading control).
(C) ABCA1 RNA from HIV-infected macrophages used for Western blotting in (A) was analyzed by real-time RT-PCR. Results were adjusted according to
b-actin signal and are presented in arbitrary units; an asterisk (*) indicates p , 0.01 (versus mock).
(D) RNA was extracted from non-activated RAW 264.7 cells (control), mock-transfected RAW cells activated with LXR agonist TO-901317 (LXR), or cells
transfected with SF2-derived Nef and activated with TO-901317 (LXRþNefSF2), and analyzed by real-time RT-PCR. Results were adjusted according to
28S RNA signal and are presented in arbitrary units; an asterisk (*) indicates p , 0.01 (versus LXR agonist-treated, mock-transfected cells).
DOI: 10.1371/journal.pbio.0040365.g003
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endocytic vesicles [36], and demonstrated the role of endo-
somal ABCA1 and trafﬁcking of ABCA1 between endosomes
and plasma membrane in the apoA-I–mediated efﬂux of
cellular lipids from the endosomal compartment [38,39].
Figure 4A and 4B show p24 staining, and Figure 4C and 4D
show ABCA1 distribution in human macrophages infected
with DNef and Nef-expressing HIV-1, respectively. Consistent
with the ﬁndings of Neufeld and colleagues [36], ABCA1 was
distributed evenly between the cytoplasm and the plasma
membrane in human macrophages either uninfected (un-
published data) or infected with DNef HIV-1 (Figure 4C), as
well as in mock-transfected murine RAW 264.7 cells (Figure
4E). It appears that in macrophages infected with Nef-
expressing HIV-1, ABCA1 was re-localized to the cell
periphery (p24
þ cells in Figure 4D). This re-localization of
ABCA1 to the plasma membrane was even more pronounced
in Nef-transfected murine macrophages RAW 264.7 (compare
Figure 4E and 4F). No re-localization of ABCA1 was observed
in macrophages transfected with Nef.G2A (Figure 4G).
Therefore, Nef expression induces re-localization of ABCA1,
which requires myristoylation of Nef.
Previous studies demonstrated that apoA-I speciﬁcally
binds to ABCA1 at the cell surface [40–42]. It was also
suggested that trafﬁcking of apoA-I to intracellular choles-
terol pools correlates with trafﬁcking of ABCA1 [39,43].
Consistent with re-localization of ABCA1 to the plasma
membrane, the speciﬁc binding of [
125I]apoA-I to Nef-
transfected RAW 264.7 macrophages was increased (Figure
4H, left panel). However, internalization of [
125I]apoA-I was
almost completely blocked, supporting the model whereby
Nef impairs intracellular trafﬁcking of ABCA1 (Figure 4H,
right panel). Degradation of [
125I]apoA-I was negligible and
was not affected by Nef (unpublished data).
Therefore, Nef-dependent changes in intracellular distri-
bution of ABCA1 may be another mechanism responsible for
impairment of cholesterol efﬂux.
Nef Interacts with ABCA1
Nef has been shown to modulate expression of several
trans-membrane proteins. In some cases (e.g., with CD4 or
major histocompatibility complex [MHC] I) Nef down-
regulates the protein, and in some (e.g., with invariant chain
of MHC class II or with dendritic cell-speciﬁc ICAM-3-
grabbing nonintegrin [DC-SIGN]), it up-regulates the pro-
tein’s surface expression ([44] and references therein). Some
of these effects, including down-regulation of CD4 [45] and
MHC I [46], have been shown to depend on an interaction
between Nef and the target protein. We therefore tested
whether Nef interacts with ABCA1. HeLa cells were co-
transfected with Nef or Nef.G2A and FLAG-tagged ABCA1,
ABCA1 was immunoprecipitated using anti-FLAG antibody,
and immunoprecipitates were analyzed for co-precipitation
of Nef. This analysis revealed that Nef co-precipitated with
ABCA1, whereas Nef.G2A did not (Figure 5A, upper panel)
despite equally high expression of the two forms of Nef
(Figure 5A lower panel). We conclude that Nef can interact
with ABCA1, and this interaction requires myristoylation of
Nef and correlates with the ability of Nef to impair
cholesterol efﬂux. The Nef-speciﬁc signal observed in this
experiment required high-level expression of participating
Figure 4. The Effect of Nef on ABCA1 Localization
(A–D) On day 5 after infection with VSV-G-pseudotyped Nef-expressing
(B and D) or DNef (A and C) HIV-1 SF2, cells were co-stained with anti-p24
mouse monoclonal and anti-ABCA1 rabbit polyclonal antibodies,
followed by FITC-conjugated anti-mouse (A and B) and Cy5-conjugated
anti-rabbit IgG (C and D). Arrows point to cells with re-localized ABCA1.
The scale bars represent 20 lm.
(E–G) Distribution of ABCA1 revealed by staining with monoclonal anti-
ABCA1 antibody and FITC-conjugated anti-mouse IgG in RAW 264.7 cells
transfected with empty vector (E), WT Nef derived from SF2 HIV-1 (Nef.wt,
panel [F]), or SF2 Nef carrying a G2A mutation (Nef.G2A, [G]). Insets in (E
and F) show cross-section of the image reconstituted from serial
sectioning. Scale bars represent 20 lm.
(H) [
125-I]apoA-I binding (left panel) and internalization (right panel) in
RAW 264.7 macrophages transfected with HIV-1 SF2-derived Nef. An
asterisk (*) indicates p , 0.01.
DOI: 10.1371/journal.pbio.0040365.g004
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with ABCA1.
Interaction between ABCA1 and Nef at the plasma
membrane was supported by confocal microscopy, which
demonstrated co-localization of Nef and ABCA1 in RAW
264.7 cells transfected with Nef.wt-expressing vector (Figure
5B). No co-localization was observed between ABCA1 and
Nef.G2A (Figure 5B). This visual analysis was reinforced by an
analytical quantiﬁcation presented in Figure 5C. Indeed, both
ABCA1 and the WT Nef proteins are found at the cell
periphery, and their co-localization is indicated by over-
lapping green and blue peaks at either end of the graph.
Moreover, both colors peak and valley in tandem, suggesting
a correlation in subcellular localization of ABCA1 and WT
Nef. No such correlation is observed in ABCA1 and Nef.G2A
distribution. Taken together, these results suggest that
interaction between ABCA1 and Nef occurs at the cell
plasma membrane.
Therefore, both re-localization and down-modulation of
Figure 5. Nef Interacts with ABCA1
(A) ABCA1 was immunoprecipitated using anti-FLAG M2 affinity gel from HeLa cells co-transfected with ABCA1-FLAG and an empty vector (mock), WT
SF2 Nef (Nef.wt), or myristoylation-defective mutant Nef.G2A. Immunoprecipitates were analyzed by Western blotting for Nef (upper panel) or ABCA1
(middle panel) using specific antibodies. Bottom panel shows Nef expression in lysates of cells used for immunoprecipitation.
(B) Experiment was performed as in Figure 4E, except that cells were incubated with monoclonal anti-ABCA1 and polyclonal anti-Nef antibody, followed
by FITC-conjugated anti-rabbit and Cy5-conjugated anti-mouse antibodies. Since all transfected cells show re-localization of ABCA1 (Figure 4E), a typical
single cell is shown here. Images were analyzed using software on the Zeiss LSM 510 microscope. The scale bar represents 20 lm.
(C) Fluorescence profile of the image in Figure 5B was analyzed using the LSM 510 software. The top panel shows the distributions of the ABCA1 and
HIV-1 Nef proteins in blue and green, respectively. The same analysis in the lower panel was performed for ABCA1 (blue) and Nef.G2A (green). The co-
localization of WT Nef and ABCA1 at the plasma membrane is indicated by overlapping green and blue peaks at either end of the graph in the top
panel.
DOI: 10.1371/journal.pbio.0040365.g005
PLoS Biology | www.plosbiology.org November 2006 | Volume 4 | Issue 11 | e365 1975
HIV Impairs Cholesterol EffluxABCA1 depend on its interaction with Nef, which in turn
requires myristoylation and membrane localization of Nef.
HIV-Infected Macrophages Transform into Foam Cells
To determine whether impairment of cholesterol efﬂux by
HIV-1 infection leads to cholesterol accumulation and foam
cell formation, we loaded macrophages (uninfected or
infected with Nef-expressing or DNef HIV-1) with lipids by
incubating with acetylated LDL (AcLDL) in the presence of
apoA-I and stained cellular lipids with Oil Red O (Figure 6).
This experiment revealed formation of typical lipid-rich cells
in cultures infected with Nef-expressing HIV-1, whereas
uninfected cells or macrophages infected with DNef virus
accumulated substantially less cholesterol (compare Figure
6A, 6B, and 6C). Analysis by transmission electron microscopy
revealed more lipid vacuoles (arrows in Figure 6E) in
macrophages infected with Nef-expressing HIV-1 than in
uninfected cells or cells infected with DNef HIV-1 (compare
Figure 6D, 6E, and 6F). Cholesterol loading of RAW 264.7
macrophages transfected with Nef also led to accumulation of
signiﬁcantly larger amounts of lipids when compared to cells
transfected with an empty vector (compare Figure 6H and 6I).
In addition, Nef-transfected RAW 264.7 macrophages dem-
onstrated accelerated cholesteryl ester synthesis, especially
when cells were loaded with AcLDL (Figure 6G). Enhanced
synthesis of cholesteryl esters is a sensitive indicator of
accumulation of cholesterol inside the cells and a key element
of foam cell formation.
Measurements of cholesterol mass conﬁrmed substantially
higher cholesteryl ester content in Nef-transfected RAW
264.7 macrophages compared to mock-transfected cells
(Figure 7A); there was also more free cholesterol in the
transfected macrophages (Figure 7B). Synthesis of triglycer-
ides was not affected (Figure 7C), indicating that increased
cholesteryl ester synthesis and content is a consequence of
increased concentration of cholesterol rather than of fatty
acids. The increased cholesterol content in Nef-transfected
cells was not caused by differences in AcLDL uptake, as the
latter was similar between Nef-transfected and mock-trans-
fected cells (Figure 7D). To accommodate the increasing
amounts of cholesteryl esters, cells would require an addi-
tional amount of phospholipids, and, indeed, the efﬂux of
phospholipids was inhibited (Figure 2A), whereas phospholi-
pid synthesis was accelerated in Nef-transfected cells (Figure
7E). Taken together, these results indicate that HIV-1
infection, via Nef expression, impairs reverse cholesterol
transport in macrophages and leads to accumulation of lipids
and formation of foam cells.
HIV-Positive Foam Cells in Atherosclerotic Plaques of HIV-
Infected Patients
Our ﬁnding that HIV-1 infection of macrophages impairs
cholesterol efﬂux from these cells suggests that HIV-infected
macrophages may potentially contribute to the development
of atherosclerotic plaques, especially when combined with
dyslipidemia found in PI-treated patients. Immunostaining of
sections of atherosclerotic plaques obtained from highly
active antiretroviral therapy (HAART)-treated HIV-infected
patients demonstrated the presence of p24
þ macrophages
(Figure 8A, 8B, 8E, and 8F). In areas surrounding lipid cores,
some p24
þ cells displayed a typical foam cell appearance
(Figure 8B). Analysis of parallel consecutive sections stained
with anti-CD68 showed that these p24
þ cells were located in
areas composed of CD68
þ cells (Figure 8C), indicating the
macrophage nature of p24
þ foam cells. Double immunostain-
ing conﬁrmed this notion by demonstrating the association of
p24 staining with CD68
þ macrophages and macrophage foam
cells (Figure 8E and 8F). These ﬁndings indicate that HIV-
infected, cholesterol-loaded macrophages are present in the
atherosclerotic plaque and therefore may potentially be
involved in pathophysiological events leading to the develop-
ment of atherosclerosis.
Active Cholesterol Efflux Reduces Infectivity of HIV Virions
To determine whether impairment of cholesterol efﬂux has
a role in HIV biology, we compared infectivity of HIV virions
produced from monocyte-derived macrophages stimulated or
not with an LXR agonist, TO-901317. We hypothesized that if
impairment of cholesterol efﬂux is a speciﬁc mechanism to
increase HIV replication, then agents counteracting this
effect should have anti-HIV activity. LXR agonists up-
regulate expression of ABCA1 at a transcriptional level and
stimulate cholesterol efﬂux from various cell types, including
human monocyte-derived macrophages ([47] and Figure 9A).
When added to HIV-infected macrophages at day 7 after
infection and kept with cells for another 7 d (to allow ABCA1
to accumulate and overcome Nef-mediated inhibition), LXR
agonist prevented the impairment of cholesterol efﬂux by
HIV-1 infection (Figure 9A); in fact, cholesterol efﬂux from
TO-901317–treated HIV-infected macrophages was similar to
efﬂux from uninfected cells stimulated with the LXR agonist.
The lack of HIV-speciﬁc reduction of cholesterol efﬂux is
likely due to overproduction of ABCA1, which exceeds
production of Nef. Virions were collected from TO-901317–
treated and untreated cells, adjusted according to p24
content, and analyzed for infectivity using indicator P4-
CCR5 cells. This analysis revealed a substantial reduction (by
about 80%) of infectivity of virions produced from macro-
phages treated with LXR agonist (Figure 9B). Interestingly,
protein composition of the virions produced from LXR
agonist–treated and untreated cells was very similar (unpub-
lished data), whereas virion-associated cholesterol was sig-
niﬁcantly diminished in virions produced from TO-901317–
treated macrophages (Figure 9C). These results suggest that
stimulation of cellular cholesterol efﬂux may be an effective
approach to suppressing HIV replication.
Discussion
Results presented in this report demonstrate that HIV-1,
via the accessory protein Nef, impairs cholesterol efﬂux from
macrophages. This ﬁnding can be interpreted as a virus-
mediated switch of cholesterol trafﬁcking from physiological
efﬂux to virus-controlled transport, thus reducing the ability
of a cell to export excessive cholesterol. Given that
availability of cholesterol is critical for HIV assembly and
infectivity [48], it is physiologically sensible for the virus to
take over control of intracellular cholesterol metabolism.
A previous report demonstrated that Nef binds cholesterol
and may deliver it to nascent virions [5]. Our study suggests
that Nef-mediated impairment of cholesterol efﬂux is
another mechanism ensuring efﬁcient delivery of cholesterol
to HIV. Importantly, this mechanism may be a necessary
component of the above-mentioned Nef-mediated transport
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HIV Impairs Cholesterol EffluxFigure 6. Accumulation of Lipids in Cells Infected with HIV-1 or Transfected with Nef
(A–C) Oil Red O staining of HIV-infected macrophages. Uninfected (A) macrophages or cells infected with VSV-G–pseudotyped Nef-positive (B) or DNef
(C) HIV-1 SF2 variants were loaded with cholesterol on day 3 after infection by incubating with AcLDL in the presence of apoA-I, and lipids were stained
with Oil Red O 24 h later. p24 concentration in the culture supernatant on day 3 after infection was 4.7 ng/ml for cells inoculated with Nef-positive virus
and 9.8 ng/ml for the culture inoculated with DNef HIV-1.
(D–F) Electron microscopy of cholesterol-loaded uninfected macrophages (D) and cells infected with Nef-positive (E) and DNef (F) HIV-1 AD8 performed
14 d after infection. Uninfected cells have small numbers of electron-lucent lipid vacuoles (arrows). The cytoplasm of cells infected with Nef-positive
virus is filled with electron-dense lipid vacuoles (arrows). Cells infected with DNef virus have small numbers of electron-lucent lipid vacuoles (arrows),
similar in number to those in uninfected cells. The scale bars represent 5 lm.
(G) The effect of Nef on cholesteryl ester synthesis. The rate of cholesteryl ester synthesis in RAW 264.7 cells transfected with an empty vector (mock-
transfected) or Nef-expressing construct and incubated with or without AcLDL in the presence of apoA-I or 5% human plasma is presented as mean 6
SD of quadruplicate determinations. An asterisk (*) indicates p , 0.02.
(H) and (I) RAW 264.7 cells were transfected with empty vector (H) or Nef-expressing construct (I), stimulated with LXR agonist, incubated with AcLDL
and lipid-free apoA-I, fixed with formaldehyde, and stained with Oil Red O.
DOI: 10.1371/journal.pbio.0040365.g006
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HIV Impairs Cholesterol Effluxof cholesterol to virions. Indeed, prevention of cholesterol
efﬂux impairment by LXR agonist reduces virion-associated
cholesterol without interfering with Nef incorporation into
the virions (unpublished data). Reduction of virion-associated
cholesterol correlates with lower virion infectivity (Figure 9B
and 9C).
Our results demonstrate that Nef speciﬁcally targets
ABCA1. Indeed, Nef did not suppress cholesterol efﬂux in
cells lacking ABCA1 (HeLa cells or non-activated RAW 264.7
cells), but did so in ABCA1-expressing cells, such as RAW
264.7 cells stimulated with an LXR agonist, HeLa cells
transfected with ABCA1, and differentiated human macro-
phages. Furthermore, Nef did not suppress cholesterol efﬂux
from ABCG1-transfected HeLa cells (Figure 2E). These
ﬁndings and the fact that Nef can interact with ABCA1
(Figure 5A) suggest that there is an interplay between Nef and
ABCA1 in an HIV-infected cell. The end result of this
interplay would depend on relative levels of expression of Nef
and ABCA1. Consistent with this suggestion, overexpression
of Nef from the cytomegalovirus (CMV) promoter inhibits
ABCA1-mediated cholesterol efﬂux stimulated with the LXR
agonist (Figure 1C), whereas levels of Nef expressed from the
HIV LTR are insufﬁcient to suppress LXR agonist-stimulated
cholesterol efﬂux in HIV-infected macrophages (Figure 9A).
As a result, HIV infectivity is reduced in LXR agonist-
stimulated cells (Figure 9B). Therefore, drugs stimulating
cholesterol efﬂux may provide a dual beneﬁt to HIV-infected
patients by limiting HIV replication and reducing the risk of
atherosclerosis.
Our studies show that cholesterol efﬂux impairment is a
Figure 7. Analysis of Lipids in RAW 264.7 Macrophages Transfected with
Nef
(A) Cholesteryl ester content after 24 h incubation with AcLDL (50 lg/ml)
determined by enzymatic assay; an asterisk (*) indicates p , 0.01.
(B) Free cholesterol content after 24 h incubation with AcLDL (50 lg/ml)
determined by enzymatic assay; an asterisk (*) indicates p , 0.05.
(C) Triglyceride biosynthesis after 24 h incubation with AcLDL (50 lg/ml)
measured as incorporation of [
14C]oleic acid into triglycerides as
described in Materials and Methods.
(D) Uptake of AcLDL was calculated as a sum of
125I-AcLDL specifically
taken up and degraded by cells.
(E) Phospholipid biosynthesis measured as incorporation of [
14C]choline
into phospholipid fraction as described in Materials and Methods; an
asterisk (*) indicates p , 0.01.
DOI: 10.1371/journal.pbio.0040365.g007
Figure 8. Identification of HIV-1–Positive Macrophages in Atherosclerotic
Plaques of HIV-Infected Subjects.
Single (A–D) and double (E and F) immunostaining of aortic wall
segments.
(A) p24 staining. A low-magnification image showing the presence of
p24
þ cells in an area adjacent to the plaque lipid core. The scale bar
represents 100 lm.
(B) Detail of (A). p24
þ cells show a characteristic morphology of foam
cells. The scale bar represents 10 lm.
(C) CD68 staining. CD68
þ cells were identified in a parallel consecutive
section to that shown in (A). The scale bar represents 100 lm.
(D) Negative control (staining with an irrelevant primary antibody). The
scale bar represents 100 lm.
(E) Double immunostaining showing the co-localization of p24 (brown)
with CD68 (rose). Immunostaining included a combination of a rabbit
polyclonal anti-p24 antibody in the peroxidase–anti-peroxidase system
with DAB chromogen yielding a brown reaction product, and a mouse
monoclonal antibody to CD68 in the alkaline phosphatase–anti-alkaline
phosphatase system with Fast Red chromogen, resulting in a rose
precipitate. Counterstaining was with Mayer’s hematoxylin. The scale bar
represents 50 lm.
(F) A detail of (E). The scale bar represents 15 lm.
DOI: 10.1371/journal.pbio.0040365.g008
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HIV Impairs Cholesterol Effluxconserved feature of HIV-1 Nef. Indeed, we show this
phenomenon using three R5 (ADA, Yu-2, and 92US660) and
two X4 (SF2 and LAI) HIV-1 isolates. We demonstrate that
HIV-1 Nef impairs cholesterol efﬂux by at least two
mechanisms: it reduces ABCA1 abundance, and it causes
intracellular re-distribution of ABCA1. These two mecha-
nisms may be related, as they both depend on interaction
between Nef and ABCA1 (Figures 3–5). For example, a block
to intracellular trafﬁcking of ABCA1 may re-target this
protein to a degradation pathway. Alternatively, ABCA1 re-
distribution and down-regulation may be two independent
effects of Nef, both contributing to impairment of cholesterol
efﬂux. Indeed, several recent reports demonstrated a role of
ABCA1 trafﬁcking between late endosomes and the cell
surface in cholesterol efﬂux from endosomal compartment
[36,38,39,49]. The effects of Nef on ABCA1 distribution and
apoA-I binding and internalization are similar to the effects
of cyclosporin A [43] or deletion of the PEST sequence in
ABCA1 [39], both of which inhibit efﬂux of cholesterol from
late endosomes. Therefore, both down-regulation of ABCA1
and its intracellular re-distribution can independently con-
tribute to cholesterol efﬂux impairment observed in HIV-
infected cells. Interestingly, Nef alone had less effect on
ABCA1 abundance than HIV-1 infection (compare Figure 3A
and 3B), however, it had a more profound effect on the
sequestration of ABCA1 at the plasma membrane (compare
Figure 4D and 4F). Although this result may be due to
differences between the cell types in which these analyses
were performed (primary human macrophages for HIV
infection and murine macrophage cell line RAW 264.7 for
Nef transfection), it is also possible that the primary effect of
Nef is to sequester ABCA1 at the plasma membrane, and
some other HIV protein may cooperate with Nef to stimulate
down-regulation of sequestered ABCA1.
The exact molecular mechanisms responsible for the effect
of Nef on intracellular trafﬁcking and abundance of ABCA1
are yet to be fully investigated. Nef is known to regulate
expression of several transmembrane proteins, including
CD4 [45], MHC I [50], MHC II [50], CD28 [51], and DC-SIGN
[52]. In most cases, Nef mediates internalization and
degradation of the receptor [53], but in some cases (e.g., with
DC-SIGN or invariant chain of MHC II), it up-regulates the
cell surface expression of the protein. These effects are
consistent with our ﬁndings showing ABCA1 re-localization
and down-regulation, which may involve mechanisms similar
to those described for Nef interactions with other proteins. It
is worth noting that few of the above-mentioned studies
showed co-immunoprecipitation of Nef with a target protein
from HIV-infected cells, consistent with our inability to pull
down Nef and ABCA1 from HIV-infected macrophages. This
may be due to a transitory nature of Nef–ABCA1 interaction
and low-level expression of these proteins. Analysis of this
interaction in cells overexpressing both proteins demonstra-
ted a critical role of Nef myristoylation (Figure 5A). This fatty
acid may either be directly involved in binding of Nef to
ABCA1, similar to the role that farnesylation of the yeast
pheromone a-factor plays in its interaction with the yeast
ABC transporter Ste6 [54], or it may regulate Nef–ABCA1
interaction indirectly by targeting Nef to the plasma
membrane. Further analysis of the mechanisms by which
Nef affects ABCA1 function would require understanding of
the molecular events that regulate intracellular trafﬁcking
and degradation of ABCA1 in uninfected cells, which is
incompletely characterized and is a subject of the ongoing
studies.
The results of this study have potential implications for
understanding pathogenesis of CAD in HIV-infected patients.
These patients have a mildly elevated risk of CAD [55], which
is sharply raised by treatment with certain PIs [7,9,14,19].
Increased risk of CAD after treatment with PIs led to the
Figure 9. Cholesterol Efflux and Infectivity of HIV Virions
Human monocyte-derived macrophages were infected with HIV-1 ADA or mock-infected, and 7 d after infection were treated or not treated with LXR
agonist, TO-901317 (500 nM), for seven more days.
(A) Cholesterol efflux to apoA-I was measured on day 21 after infection. An asterisk (*) indicates p , 0.01 (versus uninfected cells not treated with TO-
901317); a number sign (#) indicates p , 0.01 (versus HIV-infected cells not treated with TO-901317).
(B) Virions were collected from culture supernatants of LXR agonist-treated and untreated (control) cells on day 10 and day 14 (pooled together),
adjusted according to p24 content, and analyzed for infectivity on indicator P4-CCR5 cells. Experiment was performed in triplicate, and results (mean 6
SD) are presented as percent infectivity of virions produced by control cells; an asterisk (*) indicates p , 0.001.
(C) Incorporation of [
3H]cholesterol into virions produced by LXR agonist-treated and untreated (control) cells was measured in triplicate, and results
(mean 6 SD) are presented relative to cholesterol in the virions produced by control cells; an asterisk (*) indicates p , 0.001.
DOI: 10.1371/journal.pbio.0040365.g009
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HIV Impairs Cholesterol Effluxassumption that PIs and/or dyslipidemia are the primary
source of development of atherosclerosis in HIV patients.
Results presented in this report suggest that HIV-induced
impairment of cholesterol efﬂux from macrophages may be
another important contributor to the pathogenesis of CAD.
Indeed, inactivation of ABCA1 in macrophages of hyper-
lipidemic mice signiﬁcantly increased development of athe-
rosclerosis [27], and genetic mutation inactivating ABCA1 in
humans leads to Tangier disease, one of the characteristic
features of which is an increased risk of CAD [28]. Impair-
ment of reverse cholesterol transport mediated by down-
regulation of ABCA1 has been described for bacterial
infections and has been linked to pathogenesis of athero-
sclerosis (reviewed in [56]). In the case of HIV infection, this
mechanism would have only a mild atherogenic effect or not
at all on the background of hypocholesterolemia character-
istic for untreated HIV-1 infection [55,57]. Treatment of HIV-
infected patients with HAART causes a sharp rise of
triglyceride-rich VLDL, resulting in enhanced lipid uptake
and foam cell formation [58], and small dense LDL [59,60],
which is particularly susceptible to oxidation [61], is more
able to inﬁltrate the subendothelial space, and is a risk factor
for CAD [62]. A combination of these effects of HAART and
impairment of cholesterol efﬂux by HIV (which prevents
compensatory removal of excessive cholesterol) would result
in a greatly enhanced accumulation of cholesterol in HIV-
infected macrophages and would potentially further increase
the risk of development of atherosclerosis. It should be noted
that HIV-infected macrophages, unlike T cells, survive for
extended periods of time and are considered long-term
reservoirs of HIV-1 [63]. As a result, infected macrophages
persist, at least for some time, in HAART-treated patients,
when conditions favor development of atherosclerotic pla-
ques. We can speculate that these macrophages may contrib-
ute to initiation of atherosclerotic plaque formation, which
then proceeds even in the absence of newly infected cells.
This mechanism is consistent with the presence of HIV-
infected macrophages in atherosclerotic plaques of HAART-
treated patients observed in our study (Figure 8). However,
further in vivo and clinical studies are required to evaluate
the contribution of the impairment of reverse cholesterol
transport to the risk of atherosclerosis in HIV patients.
Findings presented in this report provide an example of
how viruses may interfere with cellular cholesterol metabo-
lism and may potentially affect the risk of atherosclerosis.
This example may be not unique to HIV. Other viruses (such
as Herpes virus or CMV) were found in atherosclerotic
plaques and were epidemiologically associated with elevated
risk of development of atherosclerosis [64–66]. Future studies
will determine whether these viruses cause disturbances in
cholesterol metabolism similar to those found in this report.
In support of this possibility, several reports demonstrated
that bacterial and viral pathogens may modulate macrophage
cholesterol efﬂux by down-regulating ABC transporters via
LXR-dependent [24] and LXR-independent [25] pathways.
The ﬁrst pathway is engaged after activation of Toll-like
receptors by invading viruses or bacteria. The second
pathway involves the negative effect of bacterial endotoxin
on ABCA1 mRNA levels in macrophages [25]. Both pathways
promote conversion of macrophages into foam cells, which
may acquire resistance to pathogen, but retain their
atherogenic properties [12]. Therefore, the effect on reverse
cholesterol transport may be a common feature of viral and
bacterial infection of macrophages, although mechanisms
involved are likely unique for each infection.
Materials and Methods
Human monocyte-derived macrophage cultures. Monocyte-derived
macrophages were prepared from peripheral blood mononuclear
cells of normal donors using adherence to plastic, and differentiated
in the presence of macrophage colony-stimulating factor essentially
as previously described [67]. No stimulation with LXR agonist was
performed unless indicated.
Antibodies. The following antibodies were used for Western
blotting: rabbit polyclonal anti-ABCA1 (Novus Biologicals, Littleton,
Colorado, United States), rabbit polyclonal and mouse monoclonal
anti-Nef (AIDS Research and Reference Reagent Program), rabbit
polyclonal anti-ABCG1 (Novus Biologicals), rabbit polyclonal anti-
SR-B1 (Novus Biologicals), and mouse monoclonal anti-b-actin
(Sigma, St. Louis, Missouri, United States).
Viruses and infections. Macrophage-tropic HIV-1 strains Yu-2 and
92US660 were obtained from the National Institutes of Health (NIH)
AIDS Research and Reference Reagent Program. VSV-G–pseudo-
typed HIV-1 was prepared by co-transfecting HEK 293T cells with
Env-deﬁcient HIV-1 infectious clones [5] and VSV-G-expressing
plasmid pHEF-VSVG [68]. All infections were performed using 3.5 3
10
6 cpm of RT activity per 10
6 cells.
FACS analysis of HIV-infected macrophages. To determine the
percentage of HIV-infected cells, HIV-infected macrophages were
detached from the plate, ﬁxed in 4% formalin/PBS, permeabilized
using Becton-Dickinson permeabilization/washing solution (15 min at
4 8C), and incubated with PE-conjugated anti-p24 monoclonal
antibodies (mAb) or isotype control IgG for 30 min at 4 8C. After
washing, cells were analyzed on a FACScan ﬂow cytometer (Becton-
Dickinson, Palo Alto, California, United States).
Transfection. RAW 264.7 mouse macrophage cells were transiently
transfected using the DEAE-dextran method and 5-azacytidine as
described previously [69]. The efﬁciency of transfection was 80%–
90%. HEK 293T and HeLa cells were transfected using Metafectene
reagent (Biontex, Munich, Germany) following the manufacturer’s
protocol. The efﬁciency of transfection was 80%.
Cholesterol and phospholipid efﬂux from RAW 264.7 cells. RAW
264.7 cells were incubated in labeling medium containing [
3H]cho-
lesterol (75 kBq/ml) or [methyl-
14C]choline (0.2 MBq/ml) for 48 h.
Cells were then incubated for 18 h in serum-free medium in the
presence of the LXR agonist TO-901317 (ﬁnal concentration 1 lM) to
stimulate ABCA1 expression and cholesterol efﬂux. Cells were then
washed with PBS and incubated for 3 h in either serum-free medium
alone (blank) or in serum-free medium supplemented with 30 lg/ml
of lipid-free apoA-I or 30 lg/ml of HDL [70]. For cholesterol efﬂux
analysis, aliquots of medium and cells were counted. Phospholipids
were isolated from medium and cells by thin layer chromatography
(TLC) as described previously [71]. The efﬂux was calculated as
radioactivity in the medium/(radioactivity in the medium þ radio-
activity remaining in the cells) 3 100%. ApoA-I–dependent efﬂux is
efﬂux to apoA-I minus efﬂux to blank.
Cholesterol efﬂux from monocyte-derived macrophages and HeLa
cells. The same procedure as described above was used except that
cells were not stimulated with LXR agonist, and efﬂux was allowed to
proceed for 12 h rather than the 3 h used for RAW 264.7 cells. Efﬂux
to serum-free medium supplemented with 30 lg/ml of human serum
albumin was used as a control.
Phospholipid biosynthesis. RAW 264.7 cells were incubated in
serum-free medium containing [methyl-
14C]choline (0.2 MBq/ml) for
2 h. Cells were washed, and lipids were extracted and separated by
TLC [71]. Phospholipid biosynthesis was deﬁned as incorporation of
[
14C]choline into phospholipids per mg of cell protein per 2 h.
Cholesteryl ester and triglyceride biosynthesis and content. RAW
264.7 cells were incubated with or without AcLDL (50 lg/ml) in the
presence of 30 lg/ml of lipid-free apoA-I or 5% normolipidemic
human plasma for 2 h at 37 8C. Cells were then incubated for 2 h with
37 kBq/ml [
14C]oleic acid (presented to the cells as a BSA–sodium
oleate complex). Cells were washed, lipids extracted and [
14C]oleic
acid incorporation into cholesteryl esters and triglyceride was
measured after separation of the extracts by TLC [72]. Cellular free
and total cholesterol content were measured using enzymatic assay
(Roche, Basel, Switzerland). Free cholesterol content was calculated as
a difference between total and esteriﬁed cholesterol.
AcLDL uptake. AcLDL was labeled with
125I using Iodobeads
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the manufacturer’ instructions, the ﬁnal speciﬁc radioactivity was 100
cpm/ng protein. Cells were incubated with [
125I]AcLDL at the ﬁnal
concentration 5 lg/ml in the presence or absence of 100-fold excess of
unlabeled AcLDL for 2 h at 37 8C. The amount of degraded
[
125I]AcLDL in the medium was determined as non-iodine trichloro-
acetic acid–soluble radioactivity. Cells were then washed and counted,
and speciﬁc AcLDL uptake was calculated as a sum of cell-associated
and degraded [
125I]AcLDL after subtraction of non-speciﬁc binding
and degradation (i.e., measured in the presence of unlabeled AcLDL).
ApoA-I binding, internalization, and degradation. Human apoA-I
was labeled with
125I using Iodobeads; the ﬁnal speciﬁc radioactivity
was 200-cpm/ng protein. Cells were incubated with [
125I]apoA-I at the
ﬁnal concentration 2 lg/ml in the presence or absence of a 100-fold
excess of unlabeled apoA-I for 2 h at 37 8C. The amount of degraded
[
125I]apoA-I in the medium was determined as non-iodine trichloro-
acetic acid–soluble radioactivity. Cells were then washed, treated with
0.05% trypsin for 5 min at 37 8C to remove surface-bound [
125I]apoA-
I, and centrifuged. Radioactivity in supernatant (binding) and pellet
(internalization) was counted, and speciﬁc apoA-I binding, internal-
ization, and degradation were calculated after subtraction of non-
speciﬁc values measured in the presence of unlabeled apoA-I.
Co-immunoprecipitation of Nef and ABCA1. HeLa cells were co-
transfected with ABCA1-FLAG and Nef. At 48-h post-transfection,
cells were homogenized in PBS, and batch immunoprecipitations
using M2 afﬁnity gel (Sigma) were carried out according to the
manufacturer’s protocol. Immunoprecipitate was analyzed by West-
ern blotting using polyclonal anti-ABCA1 (Novus Biologicals) and
anti-Nef (AIDS Research and Reference Reagent Program) anti-
bodies.
Oil Red O Staining. Human monocyte-derived macrophages and
RAW 264.7 cells (stimulated with LXR agonist) were incubated with
AcLDL (50 lg/ml) in RPMI 1640 supplemented with 1% Nutridoma
(Roche) and 30 lg/ml of lipid-free apoA-I for 18 h. After washing with
PBS, cells were ﬁxed in 3.7% formaldehyde for 2 min, washed with
water, and incubated at room temperature for 1 h with Oil Red O
working solution (Fisher Biotech, West Perth, Australia). The Oil Red
O solution was removed by aspiration, the cells were washed with
water, and 0.02% sodium azide was added to the cells. The cells were
observed using a reﬂecting light microscope (903 magniﬁcation)
ﬁtted with a camera.
Fluorescent Microscopy. For visualization of ABCA1 localization,
approximately 10
6 monocyte-derived macrophages were plated into
each well of a 24-well plate containing polylysine-coated coverslips
(Becton Dickinson Labware, Bedford, Massachusetts, United States)
and infected with VSV-G pseudotyped WT or Nef-deleted HIV-1
viruses, or left uninfected. At 5-d post-infection, coverslips with
adherent macrophages were removed from the wells and washed with
PBS, and cells were ﬁxed with 4% formaldehyde (in PBS) for 20 min
at room temperature. After ﬁxing, cells were washed three times with
PBS and incubated for 1 h at room temperature in 4% goat serum (in
PBS). After washing in PBS, rabbit polyclonal antibody to ABCA1
(Novus Biologicals) and mouse monoclonal antibody to p24 [73] were
added in 4% goat serum, 0.1% BSA, and 0.1% Saponin. Anti-ABCA1
antibody was added at a 1:500 dilution and anti-p24 antibody, at
1:100. Following a 2-h incubation at room temperature, the coverslips
were washed with PBS and incubated with Cy-5–conjugated anti-
rabbit and FITC-conjugated anti-mouse secondary antibodies (Jack-
son ImmunoResearch, West Grove, Pennsylvania, United States) for 1
h at room temperature. Coverslips were mounted onto slides using
Prolong (Molecular Probes, Eugene, Oregon, United States) and
allowed to dry overnight. Visualization of stained cells was accom-
plished using a Bio-Rad MRC 1024 confocal laser scanning micro-
scope and software (Bio-Rad, Hercules, California, United States).
RAW 264.7 cells (LXR agonist-stimulated) were grown on collagen-
coated coverslips and transfected with Nef-expressing construct or an
empty vector. Cells were cultured for 48 h prior to immunostaining,
washed with PBS, ﬁxed with 4% formaldehyde, and quenched with 50
mM NH4Cl. After permeabilization with 0.5% Triton X-100, cells
were incubated with the monoclonal anti-ABCA1 antibody NDF4C2
for 1 h, washed with PBS, and incubated in the dark with a secondary
goat anti-mouse FITC-labeled antibody for 1 h. For co-localization
analysis, monoclonal anti-ABCA1 and polyclonal anti-Nef antibody
were used, followed by Cy5-conjugated anti-mouse (staining ABCA1
in blue) and FITC-conjugated anti-rabbit (staining Nef in green)
antibodies. Cells were washed again with PBS and, after mounting
onto glass slides, were studied using Zeiss META confocal microscope
(Zeiss, Oberkochen, Germany). Image analysis was performed using
the LSM 510 software of the Zeiss microscope which analyzes the
distribution of the ﬂuorescence along cell section.
Transmission electron microscopy. Macrophages infected with
HIV-1ADA were ﬁxed in 2.5% neutral-buffered glutaraldehyde,
pelleted, gelled into agar, post-ﬁxed in 1% OsO4, block-stained in
uranyl acetate, dehydrated in graded ethanol and propylene oxide,
and embedded in Spurr’s resin. Thin sections were stained with
uranylacetate and lead citrate, and examined on a LEO EM10
electron microscope (LEO Electron Microscopy, Thornwood, New
Jersey, United States) at 60 kV.
Real-Time RT-PCR. cDNA was prepared from total cellular RNA
from human monocyte-derived macrophages and analyzed by QPCR
using IQ Sybr Green Supermix from Bio-Rad according to the
manufacturer’s recommendations with the following primers (300 nM
of each primer per sample): ABCA1 sense, 59-GAGCCTCCCCAG-
GAGTCG-39; ABCA1 antisense, 59-CAAACATGTCAGCTGTTACTG-
GAAG-39; b-actin sense, 59- GCCGTACCACTGGCATCGTG-39; b-
actin antisense, 59-GTGGTGGTGAAGCTGTA-39. Primers were or-
dered from Integration DNA Technologies (Coralville, Iowa, United
States). Serial dilutions of ABCA1-pTRE [35] and b-actin cDNA
(QPCR Plasmid Standard from Invitrogen, Carlsbad, California,
United States) plasmids were used to calculate the copy number of
ABCA1 and b-actin cDNA per sample, and results were adjusted
according to b-actin cDNA levels. The abundance of ABCA1-speciﬁc
RNA in RAW cells was determined as described previously [72].
Autopsies. Segments of the aortic wall were removed at autopsy
from four HAART-treated AIDS patients (males, aged 39, 40, 44, and
47 y) at the Institute of Forensic Medicine, Sydney, Australia. The
specimens were ﬁxed in formalin and embedded in parafﬁn. Parallel
sections were immunostained with the p24 antibody to detect HIV-1,
and anti-CD68 antibody to identify macrophages. Single and double
(using DAKO-DOUBLESTAIN Kit System 40; Dako, Glostrup, Den-
mark) immunostaining was carried out as described previously [74].
Sections of lymph nodes excised from the AIDS patients served as a
positive control.
Infectivity assay. Virus infectivity was analyzed using P4-CCR5
indicator cells [75] that express b-galactosidase under control of HIV-
1 LTR. Brieﬂy, cells were seeded into a 96-well plate at a density of
7,500 cells per well and allowed to adhere overnight. The medium was
then removed and replaced with virus in suspension (normalized
according to RT activity) or with fresh medium as a control. Infection
was allowed to proceed for 48 h at 37 8C, then the virus was removed,
and 100 ll of lysis buffer (b-Galactosidase Enzyme Assay System;
Promega, Madison, Wisconsin, United States) was added. The plate
was then frozen overnight at  70 8C to ensure efﬁcient lysis. Upon
thawing, 50 ll of lysate was placed into a new 96-well plate, and 50 ll
of 23Assay Buffer was added. The plate was incubated at 37 8C for 1.5
h and optical density (OD) readings were taken at 420 nm.
Analysis of virion-associated cholesterol. Seven days post-infection
with HIV-ADA, [
3H]cholesterol was added to the cultures at a ﬁnal
concentration of 75 kBq/ml. At 24 h after addition of cholesterol, the
labeled medium was removed, the cells were washed with PBS, and
the new medium was added with or without 500 nM of LXR agonist,
TO-901317 (Sigma). Culture supernatants were collected every 3 d
over the period of 2 wk and pooled; virions were pelleted by
ultracentrifugation and normalized according to p24 value, and the
amount of incorporated [
3H]cholesterol was counted on a beta-
counter.
Statistical analysis. All experiments were reproduced two to four
times, and representative experiments are shown. The Student t test
was used to determine statistical signiﬁcance of the differences.
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